http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
-
Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2
-
Castle Biosciences to Host Second Annual Castle Cares Charity Walk
-
Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year
-
Castle Biosciences Inc. (CSTL) to Present New DecisionDx-SCC and DecisionDx-Melanoma Data
-
Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer
-
Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology
-
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Castle Biosciences (CSTL) Presents New Data Demonstrating the Ability of DecisionDx-SCC to Identify Tumors Likely to Metastasize
-
Castle Biosciences Presents New Data Demonstrating the Ability of DecisionDx®-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Tradit
-
Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational De
-
Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting
-
Castle Biosciences (CSTL) Announces IDgenetix Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
-
IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
-
Castle Biosciences Celebrates Skin Cancer Awareness Month
-
Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council
-
Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh
-
Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
-
Castle Biosciences Reports First Quarter 2023 Results
-
Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance
-
Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event
-
DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
-
TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia
-
Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3
-
Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference
-
Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Cent
-
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
-
Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
-
Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society f
-
Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results
-
Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing
-
Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors
-
Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the C
-
Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023
-
Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year
-
Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023
-
Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
-
Castle Biosciences Inc. (CSTL) Reports Prelim Q4 Results
-
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results
-
Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory
-
Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results
-
Castle Biosciences (CSTL) Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx-SCC
-
Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors
-
Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year
-
Castle Biosciences Announces Third Quarter 2022 Results
-
Castle Biosciences to Present at Upcoming Investor Conferences
-
Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carc
-
Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
-
New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus ov
-
Castle Biosciences Inc. (CSTL) Presents New Data Demonstrating Impact of DecisionDx-SCC Test Results on Management of Medicare-Eligible Patients with cSCC and One or More Risk Factors